Twin Tree Management
ALNY icon

Twin Tree Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Twin Tree Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Sell
3,200
-5,600
-64% -$1.91M 0.02% 707
2025
Q4 		$3.5M Buy
+8,800
New +$3.89M 0.03% 642
2025
Q3 		– Sell
-36,800
Closed -$12M – 1432
2025
Q2 		$12M Sell
36,800
-11,800
-24% -$3.27M 0.02% 700
2025
Q1 		$13.1M Sell
48,600
-41,400
-46% -$10.6M 0.02% 573
2024
Q4 		$21.2M Sell
90,000
-52,300
-37% -$13.8M 0.04% 436
2024
Q3 		$39.1M Buy
+142,300
New +$37M 0.08% 221
2024
Q2 		– Sell
-2,900
Closed -$433K – 1325
2024
Q1 		$433K Sell
2,900
-12,200
-81% -$2.04M ﹤0.01% 1117
2023
Q4 		$2.89M Buy
+15,100
New +$2.57M 0.01% 987
2023
Q1 		– Sell
-83,600
Closed -$19.9M – 1257
2022
Q4 		$19.9M Hold
83,600
– – 0.04% 400
2022
Q3 		$16.7M Buy
+83,600
New +$15.9M 0.03% 413
2021
Q4 		– Sell
-4,200
Closed -$793K – 1567
2021
Q3 		$793K Sell
4,200
-38,400
-90% -$7.2M ﹤0.01% 1221
2021
Q2 		$7.22M Buy
+42,600
New +$6.24M 0.02% 601
2020
Q3 		– Sell
-15,000
Closed -$2.22M – 1197
2020
Q2 		$2.22M Sell
15,000
-7,100
-32% -$957K 0.01% 860
2020
Q1 		$2.41M Buy
22,100
+15,000
+211% +$1.73M 0.01% 670
2019
Q4 		$818K Buy
+7,100
New +$708K ﹤0.01% 889
2019
Q2 		– Sell
-20,500
Closed -$1.92M – 1218
2019
Q1 		$1.92M Buy
20,500
+19,800
+2,829% +$1.66M 0.01% 683
2018
Q4 		$51K Sell
700
-900
-56% -$69.2K ﹤0.01% 1129
2018
Q3 		$140K Buy
1,600
+200
+14% +$20.1K ﹤0.01% 946
2018
Q2 		$138K Sell
1,400
-56,300
-98% -$5.58M ﹤0.01% 1022
2018
Q1 		$6.87M Sell
57,700
-78,400
-58% -$10.1M 0.06% 280
2017
Q4 		$17.3M Buy
136,100
+62,300
+84% +$7.83M 0.13% 135
2017
Q3 		$8.67M Buy
+73,800
New +$6.3M 0.07% 260

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Tree Management's ALNY Position: Q1 2026 in Review

Twin Tree Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,641 shares — an estimated $1.24M sold.

Twin Tree Management first reported a position in ALNY in Q2 2018 and held it in 15 quarters. The position peaked at $14.6M in Q3 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Twin Tree Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Twin Tree Management sold 3,641 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
  • Twin Tree Management first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 15 quarters.
  • Twin Tree Management's Alnylam Pharmaceuticals position peaked at $14.6M in Q3 2022.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.